Загрузка...
Epithelial-to-mesenchymal transition is a resistance mechanism to sequential MET-TKI treatment of MET-amplified EGFR-TKI resistant non-small cell lung cancer cells
BACKGROUND: Tyrosine kinase inhibitor (TKI) resistance is a major obstacle in treatment of non-small cell lung cancer (NSCLC). MET amplification drives resistance to EGFR-TKIs in 5–20% of initially sensitive EGFR: mutated NSCLC patients, and combined treatment with EGFR-TKIs and MET-TKIs can overcom...
Сохранить в:
| Опубликовано в: : | Transl Lung Cancer Res |
|---|---|
| Главные авторы: | , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
AME Publishing Company
2020
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7653150/ https://ncbi.nlm.nih.gov/pubmed/33209611 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/tlcr-20-522 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|